Details : CD-001 is a Other Large Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 30, 2025
Lead Product(s) : CD-001
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
CD (Suzhou) Biopharma Announces FDA Clearance for Phase I Clinical Trial of CD-001
Details : CD-001 is built on its BsFP platform. This potential therapy, designed to target PD-1 positive CD8+ T cells, aims to address unmet medical needs in oncology and viral infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 20, 2024
Lead Product(s) : CD-001
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
